Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday newspaper round-up: Cadbury, RBS/Lloyds, Vodafone

Mon, 09th Nov 2009 06:18

Kraft, the American food company, is poised to initiate a hostile takeover bid for Cadbury today at or slightly above the offer it made in September, which valued the British confectioner at £10.2bn, according to a person familiar with the deal.Last night Kraft was finalising plans to go directly to shareholders of Cadbury before the UK Takeover Panel's "put up or shut up" deadline expires at 5pm, the Times reports.Three of the City's leading stockbrokers have written to Lord Myners, the City Minister, accusing Royal Bank of Scotland and Lloyds Banking Group of "corporate bullying" by forcing companies that owe money to the banks to use their investment banking services.In an unprecedented act of solidarity, three of the Square Mile's fiercest rivals ? Tim Linacre, chief executive of Panmure Gordon; Oliver Hemsley, chief executive of Numis; and Alex Snow, chairman of Evolution ? allege that when a company holds a rights issue to reorganise its debt, the banks will continue to lend to it only if it uses their brokerage and capital markets units for the deal, the Times reports.Insurance giant Axa Group is readying a €2bn (£1.8bn) rights issue that could be launched as early as Monday. France's biggest insurer is plotting the capital-raising to fund potential acquisitions in a sector that has been ravaged by the financial crisis. Bankers at BNP Paribas and HSBC have been appointed to work on the capital-raising, the Telegraph reports.Meanwhile, Axa Asia Pacific, the Australian-listed asset manager, has rejected an A$11bn (US$10.2bn) takeover bid from Australia's AMP, saying on Monday the cash and shares proposal undervalued its business. The offer is one of the largest in the global financial services industry since the onset of the financial crisis, excluding transactions involving government bail-outs, and is also among the biggest in Asia this year, the FT reports.Vittorio Colao, Vodafone's chief executive, is preparing a fresh round of cost cutting as he tries to offset falling revenue at the mobile phone operator. Vodafone's shares have underperformed the FTSE 100 by 16 per cent this year, partly because of concern at how the UK company's underlying revenue at most of its core European businesses is falling, the FT reports.Gordon Brown, the British prime minister, rapidly backpedalled from his proposal for a financial transactions tax on Sunday after a chorus of criticism of his plan set out in a speech on Saturday to a meeting of global finance ministers. The US led a backlash against the "Tobin tax" on financial transactions after Mr Brown took a Group of 20 finance ministers' meeting by surprise with his proposal at the gathering in St Andrews, Scotland, the FT says.Britain's employers plan to continue shedding jobs during the final three months of 2009, confirming the widely held view that unemployment will continue to rise for the foreseeable future even if the UK economy comes out of recession. The outlook for UK employment prospects is now deteriorating more slowly than at any time since recession took hold in the middle of 2008, but it is still deteriorating, according to KPMG's quarterly labour market outlook, which it publishes with the Chartered Institute of Personnel and Development (CIPD), the Independent reports.Wal-Mart has sold Asda for £6.9bn to a Leeds-based investment vehicle called Corinth Services Limited for only £200m more than it paid for the UK supermarket chain in 1999. In the previously undisclosed group restructuring that took place in August, the world's largest retailer let its subsidiary Wal-Mart Stores (UK) sell 3.1bn ordinary shares in Asda in return for a £5.7bn cash payment from Corinth, a fellow Wal-Mart group company, and £1.24bn in shares, the Telegraph reports.Radioactive waste from a new generation of British nuclear power stations will be buried deep underground in a storage facility that could cost up to £18bn to build, under plans to be announced by the Government today, the Times reports.Long-dated oil prices have risen to within a whisker of $100 a barrel, in a sign that investors are expecting high prices to return after the recession. The furthest forward oil contract traded on exchanges - the December 2017 futures - rose last week to $99.97 a barrel for the Brent benchmark and to $99.43 for the West Texas Intermediate, the highest since last October. The prices have risen by 10 % in the past month, the FT reports.
More News
20 Sep 2021 14:50

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

Read more
2 Sep 2021 11:56

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Read more
13 Jul 2021 15:36

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.

Read more
13 Jul 2021 14:09

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

Read more
13 Jul 2021 11:25

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

Read more
13 Jul 2021 11:20

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Read more
9 Jul 2021 11:51

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:33

Evgen 'surprised and disappointed' by findings in SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.

Read more
6 Jul 2021 16:10

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Jun 2021 14:42

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

Read more
14 Jun 2021 13:19

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Read more
14 Jun 2021 11:00

Evgen upbeat on new data on potential breast cancer treatment

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.

Read more
26 Apr 2021 13:02

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

Read more
7 Apr 2021 16:22

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.